Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.

Slides:

Advertisements

Similar presentations

Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.

Advertisements

MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.

Single Center Experience with Drug Eluting Stents for Infrapopliteal Occlusive Disease in Patients with Critical Limb Ischemia: Mid-term follow up Robert.

Can we prevent stent restenosis after coronary stent implantation

J. Mehilli, MD, G. Richard, F-J. Neumann, S. Massberg, K-L. Laugwitz, J. Pache, J. Hausleiter, I. Ott, M. Fusaro, T. Ibrahim, A. Schömig, A. Kastrati Deutsches.

ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,

Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.

Open Repair of Ruptured Descending Thoracic and Thoracoabdominal Aortic Aneurysms in 100 Consecutive Cases Mario F. Gaudino, Christopher Lau, Monica Munjal,

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.

Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.

Decision Models Based on Individual Patient and Summary Data Mark Sculpher Neil Hawkins Centre for Health Economics, University of York Workshop: Towards.

Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.

1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.

SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.

Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.

ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.

A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park, MD, PhD, University.

Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,

Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.

AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.

Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.

RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

ΕΚΕ Hellenic PCI Registry ( ) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios.

CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.

Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.

6/9/2008 Comparative effectiveness reviews: methodological observations David B. Matchar, MD Professor of Medicine and Director, Center for Clinical Health.

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,

Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.

Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.

Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.

Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:

Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Management of ST-Elevation Myocardial Infarction

Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,

The American College of Cardiology Presented by Dr. Maurits T. Dirksen

American College of Cardiology Presented by Dr. Stephan Windecker

Giuseppe Biondi Zoccai, MD

Preventive Angioplasty in Myocardial Infarction Trial

American Heart Association Presented by Dr. Julinda Mehilli

Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Impact of Diabetes Mellitus on Long-term Outcomes in the

Maintenance of Long-Term Clinical Benefit with

Atlantic Cardiovascular Patient Outcomes Research Team

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Glenn N. Levine et al. JACC 2011;58:e44-e122

The American College of Cardiology Presented by Dr. A. Abazid

TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Cardiovascular Epidemiology and Epidemiological Modelling

Presentation transcript:

Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY

 To compare Major Adverse Cardiac Events (MACE) in Bare- metal versus drug-eluting stent in patients treated with TNK prior to being admitted to our facility for PCI.

Defined as occurrence of one of the following :  Myocardial Infarction  Target Vessel Revascularization  Death

Prehospital Fibrinolysis  Improvement in survival  Smaller infarct size  Improved ventricular healing  Reduction in the extent of left ventricular dysfunction  Greater electrical stability

 GISSI-2 and ISIS-2 – Streptokinase  GUSTO-I trial – Alteplase  GUSTO III trial compared Reteplase with Alteplase  ASSENT-2 compared Tenecteplase to Alteplase  The net effect in major thrombolytic trials has been an approximately 30 percent reduction in short-term mortality to a value of 7 to 10 percent.

PCI after fibrinolysis  There are three settings in which Percutaneous Coronary Intervention (PCI) is performed after fibrinolysis:  Facilitated PCI, in which a fibrinolytic drug is given prior to planned PCI in an attempt to achieve an open infarct-related artery before arrival in the catheterization laboratory  Rescue / Salvage PCI is defined as PCI performed within 12 hours of failed fibrinolysis (primary failure) in patients with evidence of continuing or recurrent myocardial ischemia

 Analysis of 376 consecutive patients,out of which 102 received BMS and 274 received DES from 2003 to  The 376 patients were followed for a period of 43± 17 months.  End point of follow-up was occurrence of MACE.  Choice of stent type was at the discretion of the operator.  Chi-square or Fisher’s exact test were done for categorical variables.  Student’s T test were done for continuous variables.

VariableBMS (n= 102) DES (n= 274) P value Age (years)64 ± 1263 ± 12ns Male73 (72%)197 (72%)ns Female29 (28%)77 (28%)ns Smoking48 (45%)98 (36%)ns Hypertension94 (92%)263 (96%)ns Dyslipidemia99 (97%)266 (97%)ns Diabetes mellitus39 (38%)118 (43%)ns BMI ≥ 30 kg/m²34 (33%)65 (24%)ns

VariableBMSDESP value Aspirin use101 (99%)271 (99%)ns Clopidogrel use102 (100%)274 (100%)ns Beta blockers use90 (88%)260 (95%)ns Ace Inhibitor use45 (44%)129 (47%)ns Statin use99 (97%)271 (99%)ns Follow-up (months) 42 ± 1943 ± 15ns Coronary artery bypass grafting 13 (13%)18 (7%)ns

No of vessel diseased BMSDESP value 1-vessel disease53 (52%)134(49%)Ns 2 vessel disease22 (22%)89 (32%)Ns 3 vessel disease27 (26%)51 (19%)Ns

Lesion ComplexityP value Type A34 (33%)106 (39%)ns Type B29 (29%)95 (34%)ns Type C39 (38%)73 (27%)ns Stent length (mm)27 ± 1525 ± 14ns Stent width (mm)3.2 ± ± 0.3<.0001

VariableBMS (n=102) DES (n=204) P value Myocardial infarction 4 (4%)8 (3%)ns TVR16 (16%)27 (10%)ns Death12 (12%)14 (5%)0.024 MACE25 (25%)40 (15%)0.024

Prognostic Factors Parameter Estimate Standard Error P valueHazard Ratio Prior coronary artery surgery Width of stent Bare-metal stent

 Prior CABG surgery, Decreased stent width and the use of bare-metal stents (BMS) were independent risk factors for MACE.  BMS had a 1.8 times higher incidence of developing MACE as compared to DES.  No increased rate of acute or chronic thrombosis after thrombolysis in either group. The increased rate of MACE in BMS group may be attributed to increased incidence of restenosis.

 THANK YOU